ContextVision presents Annual Report 2020 and Remuneration Report 2020

STOCKHOLM – April 7, 2021 – Please find ContextVision’s Annual Report 2020 and Remuneration Report 2020 attached. The reports can also be found on the company’s website: www.contextvision.se Printed copies of the reports will be distributed upon request by e-mail: For inquiries, please contact CFO Ann-Charlotte Linderoth E-mail:   About ContextVision ContextVision is […]
Read More

ContextVision’s second quarter sees multiple product releases including digital pathology debut

ContextVision today reports a progressive second quarter. INIFY® Prostate Screening – the company’s first decision support tool in a planned digital pathology portfolio – was granted CE-mark status, paving the way for a strong entry into the fast-growing digital pathology market. In addition, the company continues to spearhead the image enhancement market with its new next-generation ultrasound product, Rivent®.
Read More

ContextVision Sees Strongest Quarter Ever with Record Sales and Product Momentum within Digital Pathology

STOCKHOLM – April 23, 2020 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, today announced record sales and EBITDA, mainly driven by the company’s medical imaging business, despite the current global challenges. ContextVision’s first digital pathology solution continues to accelerate toward market availability. Medical Imaging Sales in Q1 ended […]
Read More

ContextVision Sees Strong Momentum in 2019 Across Medical Imaging and Digital Pathology Sectors

STOCKHOLM – February 20, 2020 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, today announced solid sales in Q4 to close out a record year for the company. With sales growth across its medical imaging offerings and patent approval for its unique method for high-quality digital pathology data generation, […]
Read More

ContextVision – Strong Q3 with solid sales, good inflow of new customers and first product in digital pathology enters beta-testing phase

ContextVision has seen a strong third quarter in 2019 as new customers have been added and the first product in digital pathology has entered the beta-testing phase. Q3 sales reached 23 MSEK and total sales are growing +5% compared to the third quarter last year. The operating result was positive 4.6 MSEK.
Read More

ContextVision – Second quarter saw commercial release of first AI-based product, Altumira™, Digital Pathology on track and record sales

ContextVision’s AI-based product Altumira™ for X-ray is now commercially available and INIFY Prostate for digital pathology will soon move to beta testing in several pathology labs. Q2 sales reached 23,1 MSEK, record sales for second quarter, 5,5% higher than Q2 2018. The operating result was positive 5,4 MSEK, mainly due to higher capitalization for product development but also supported by strong sales performance.
Read More